CINCINNATI--(BUSINESS WIRE)--June 3, 2004--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its
wholly-owned subsidiary, Viral Antigens, Inc. (VAI), has entered into
a strategic collaboration with Viral Therapeutics, Inc. (VTI), Ithaca,
NY, to support the clinical and commercial development needs of
biopharmaceutical partners. Viral Therapeutics is an expert in the
development of recombinant proteins and in production optimization.
Viral Antigens' expertise is in the areas of process development and
clinical stage manufacturing of biopharmaceuticals. The companies are
coordinating their marketing efforts to provide a wider range of
biopharmaceutical enabling technologies to better service their
clients in the development and production of recombinant proteins,
therapeutic antibodies, and vaccines.
The combined resources of VAI and VTI will provide
biopharmaceutical customers improved access to specialized service and
expertise in gene cloning, cell-line development in bacterial, insect,
mammalian and yeast cells, cell culture, fermentation, and
purification process development, and scale-up leading to production
of proteins in accordance with cGMP, the standards established by good
manufacturing practices for the pharmaceutical industry. VAI and VTI
will also provide proven experience and expertise in advanced
expression, fermentation, and purification technologies that enable
process optimization for difficult-to-express proteins.
Richard L. Eberly, General Manager, Meridian Life Science
commented, "We are excited that the combination of resources between
VAI and VTI will provide our biopharmaceutical partners the ability to
progress from discovery to clinical and commercial development in a
more efficient and expedient manner. With current biopharmaceutical
industry projections estimating 350-500 drug candidates in
development, our goal is to provide high quality and reliable
outsourcing capabilities to our industry partners."
Lee Henderson, Ph.D., CEO of Viral Therapeutics, Inc., commented,
"We are pleased to have developed this relationship with Viral
Antigens, Inc. and believe that our combined expertise and technology
offerings will provide a wide breadth of services for our current and
future clients. We expect our combined years of experience, expertise,
and technology to improve the cost effectiveness and turn-around time
for biopharmaceutical development."
Meridian is a fully integrated life science company that
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and
offers biopharmaceutical enabling technologies. Utilizing a variety of
methods, these products provide accuracy, simplicity and speed in the
early diagnosis and treatment of common medical conditions, such as
gastrointestinal, viral, urinary and respiratory infections. All
Meridian diagnostic products are used outside of the human body and
require little or no special equipment. The Company's products are
designed to enhance patient well-being while reducing the total
outcome costs of healthcare. Meridian has strong market positions in
the areas of gastrointestinal and upper respiratory infections,
serology, parasitology and fungal disease diagnosis. In addition,
Meridian is a supplier of rare reagents and specialty biologicals
along with proteins and other biologicals used by biopharmaceutical
companies engaged in research for new drugs and vaccines. The Company
markets its products to hospitals, reference laboratories, research
centers, veterinary testing centers, physician offices and diagnostics
manufacturers in more than 60 countries around the world. The
Company's shares are traded through Nasdaq's National Market, symbol
VIVO. Meridian's website address is www.meridianbioscience.com.
CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700
SOURCE: Meridian Bioscience, Inc.